AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing

According to Longevity.Technology's report of a company announcement, Immorta Bio of Miami says it has finished its planned preclinical studies of SenoMune-0257. That is a synthetic peptide, a short chain of amino acids, designed to help the immune system recognize and remove senescent cells. This article is based on that report. The company's data and the underlying paper were not reviewed.

Senescent cells are often called "zombie cells." They have stopped dividing but have not died. According to the report, the company says they contribute to chronic inflammation, tissue deterioration and the progression of many diseases. The report says the company also points to benefits from removing them in experimental models of conditions including cardiovascular disease, fibrosis, neurodegeneration and cancer, and to improved physical function and longer lifespan in mice.

Drugs that kill senescent cells directly are called senolytics. Per Longevity.Technology, Immorta cites two limits: possible off-target toxicity and the inability to build lasting immune memory. Its approach is different. The peptide is meant to prompt the body's own T cells to find and remove senescent cells.

According to the report, the company says AI helped find the peptide. Thomas Ichim, president and chief scientific officer, is quoted saying the team identified dozens of candidates and narrowed them through computational analysis and laboratory experiments to SenoMune-0257.

In laboratory studies, the report says, the peptide stimulated cytotoxic T cells, the immune cells that kill targets. These cells selectively eliminated senescent cells while sparing healthy ones, "under the conditions tested," in the company's words. The report does not give numbers, sample sizes or published data for those results.

The company describes the candidate as a potentially universal, off-the-shelf product. That would be a simpler design than the complex cellular immunotherapy it built earlier, called SenoVax. The company says the peptide is designed to offer durable immune memory, fewer off-target effects and lower manufacturing costs than personalized cell therapies. Those are design goals. They have not been shown in people.

The timeline is short. According to the report, Immorta is preparing for clinical entry in 2026, with initial human evaluation expected before year-end. The report notes the company does not say whether a regulatory application has been filed, where a trial would be held or how many people would take part. Chairman and CEO Boris Reznik called senolytic immunotherapy "a fundamental breakthrough." That is a statement of belief, not a result.

For anyone thinking about healthspan, the reality check is plain. The idea of clearing senescent cells is widely discussed. This particular approach rests on companyreported lab work, with no human data yet. Whether a peptide that worked in the lab will behave the same way in people is unknown. Nothing here is something a person can use.

What to watch next

Whether the first human dosing happens by year-end as the company expects, and whether Immorta releases detailed data or peer-reviewed results alongside it.

Faster Epigenetic Aging Linked to Higher Death Risk Across 381,000 Adults, Meta-Analysis Finds Sleep Shortened and Shifted Later as Electricity Reached Argentine Communities, Study Finds Exercise for Mild Cognitive Impairment: Network Meta-Analysis Ranking Could Not Be Confirmed FDA Clears AI Tool Estimating Alzheimer's Risk in Mild Cognitive Impairment Low Activity Plus Weak Grip Linked to Higher Cognitive Impairment Risk Review of 248 Studies Ranks Protein Plus Strength Training Top for Sarcopenia Amylin Drug Petrelintide Cut Weight Up to 9.2% in Diabetes Trial Hearing and Vision Loss Linked to Body-Mind-Memory Decline, Partly via Loneliness NAD+ and Calorie Restriction May Work Through Brain Cell Antennae in Mice Heart Amyloid Drug Tafamidis Linked to Healthier Blood Vessel Cells Eye Gene Therapy Linked to Vision Gains in Stargardt, Heads to Geographic Atrophy Trial Stair-Climb Test Gave Only Rough Estimate of Aerobic Fitness Body-Clock 'Circadian Depression' Subtype Found in a Quarter of Patients Epigenetic Age Acceleration Tracks Kidney Disease Progression in Type 1 Diabetes Most Epigenetic Aging Clocks Fail to Predict Dementia, Meta-Analysis Finds Review in Public Health Asks Whether Exercise Timing Affects Heart and Metabolic Markers Fasting Mimicking Diet Programme for Diabetes and Obesity Reaches UK Clinics AI Drug Firm Pathos Raises $237 Million, Shifts Toward Alzheimer's APA Survey: Most Americans Accept Chronic Stress, Nearly Half Withdraw Socially Tiny Peptide Alleviates Artery Calcification in Mice by Changing Cell Energy Use Hormone Therapy Linked to More Frequent, Longer Migraines After Menopause Meta-Analysis Examines Which Exercise, and How Much, Relates to Sleep in Older Adults 2,711 Autopsies Show Alzheimer's Brain Changes Are Rare Before 70 Does Pregnancy's Biological Aging Fully Reverse? A Hypothesis Awaits Testing Diet, Exercise and Empagliflozin Matched on Blood Sugar in Older Diabetics Review Finds Ultra-Processed Food Subtypes Differ Sharply in Diabetes Risk AI-Designed Peptide Targeting Zombie Cells Heads Toward First Human Testing Blocking Lactate Exporter MCT4 Improved Aged Egg Quality in Lab Study Aquatic and Dance Exercise Accompanied Lower Inflammation in Obese Older Women Aging Brain Cells Keep Their Identity, Challenging Epigenetic Drift Theory